Exploiting expression of hippo effector, yap, for expansion of functional islet mass

Nicholas M. George, Brian P Boerner, Shakeel U R Mir, Zachary Guinn, Nora E Sarvetnick

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Loss of pancreas β-cell function is the precipitating factor in all forms of diabetes. Cell replacement therapies, such as islet transplantation, remain the best hope for a cure; however, widespread implementation of this method is hampered by availability of donor tissue. Thus, strategies that expand functional β-cell mass are crucial for widespread usage in diabetes cell replacement therapy. Here, we investigate the regulation of the Hippo-target protein, Yesassociated protein (Yap), during development of the endocrine pancreas and its function after reactivation in human cadaveric islets. Our results demonstrate that Yap expression is extinguished at the mRNA level after neurogenin-3-dependent specification of the pancreas endocrine lineage, correlating with proliferation decreases in these cells. Interestingly, when a constitutively active form of Yap was expressed in human cadaver islets robust increases in proliferation were noted within insulin-producing β-cells. Importantly, proliferation in these cells occurs without negatively affecting β-cell differentiation or functional status. Finally, we show that the proproliferative mammalian target of rapamycin pathway is activated after Yap expression, providing at least one explanation for the observed increases in β-cell proliferation. Together, these results provide a foundation for manipulating Yap activity as a novel approach to expand functional islet mass for diabetes regenerative therapy.

Original languageEnglish (US)
Pages (from-to)1594-1607
Number of pages14
JournalMolecular Endocrinology
Volume29
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Proteins
Cell- and Tissue-Based Therapy
Islets of Langerhans
Cell Proliferation
Precipitating Factors
Islets of Langerhans Transplantation
Sirolimus
Cadaver
Cell Differentiation
Pancreas
Tissue Donors
Insulin
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Exploiting expression of hippo effector, yap, for expansion of functional islet mass. / George, Nicholas M.; Boerner, Brian P; Mir, Shakeel U R; Guinn, Zachary; Sarvetnick, Nora E.

In: Molecular Endocrinology, Vol. 29, No. 11, 01.11.2015, p. 1594-1607.

Research output: Contribution to journalArticle

George, Nicholas M. ; Boerner, Brian P ; Mir, Shakeel U R ; Guinn, Zachary ; Sarvetnick, Nora E. / Exploiting expression of hippo effector, yap, for expansion of functional islet mass. In: Molecular Endocrinology. 2015 ; Vol. 29, No. 11. pp. 1594-1607.
@article{96174a731d844a5cb27e77a4d7453688,
title = "Exploiting expression of hippo effector, yap, for expansion of functional islet mass",
abstract = "Loss of pancreas β-cell function is the precipitating factor in all forms of diabetes. Cell replacement therapies, such as islet transplantation, remain the best hope for a cure; however, widespread implementation of this method is hampered by availability of donor tissue. Thus, strategies that expand functional β-cell mass are crucial for widespread usage in diabetes cell replacement therapy. Here, we investigate the regulation of the Hippo-target protein, Yesassociated protein (Yap), during development of the endocrine pancreas and its function after reactivation in human cadaveric islets. Our results demonstrate that Yap expression is extinguished at the mRNA level after neurogenin-3-dependent specification of the pancreas endocrine lineage, correlating with proliferation decreases in these cells. Interestingly, when a constitutively active form of Yap was expressed in human cadaver islets robust increases in proliferation were noted within insulin-producing β-cells. Importantly, proliferation in these cells occurs without negatively affecting β-cell differentiation or functional status. Finally, we show that the proproliferative mammalian target of rapamycin pathway is activated after Yap expression, providing at least one explanation for the observed increases in β-cell proliferation. Together, these results provide a foundation for manipulating Yap activity as a novel approach to expand functional islet mass for diabetes regenerative therapy.",
author = "George, {Nicholas M.} and Boerner, {Brian P} and Mir, {Shakeel U R} and Zachary Guinn and Sarvetnick, {Nora E}",
year = "2015",
month = "11",
day = "1",
doi = "10.1210/me.2014-1375",
language = "English (US)",
volume = "29",
pages = "1594--1607",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Exploiting expression of hippo effector, yap, for expansion of functional islet mass

AU - George, Nicholas M.

AU - Boerner, Brian P

AU - Mir, Shakeel U R

AU - Guinn, Zachary

AU - Sarvetnick, Nora E

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Loss of pancreas β-cell function is the precipitating factor in all forms of diabetes. Cell replacement therapies, such as islet transplantation, remain the best hope for a cure; however, widespread implementation of this method is hampered by availability of donor tissue. Thus, strategies that expand functional β-cell mass are crucial for widespread usage in diabetes cell replacement therapy. Here, we investigate the regulation of the Hippo-target protein, Yesassociated protein (Yap), during development of the endocrine pancreas and its function after reactivation in human cadaveric islets. Our results demonstrate that Yap expression is extinguished at the mRNA level after neurogenin-3-dependent specification of the pancreas endocrine lineage, correlating with proliferation decreases in these cells. Interestingly, when a constitutively active form of Yap was expressed in human cadaver islets robust increases in proliferation were noted within insulin-producing β-cells. Importantly, proliferation in these cells occurs without negatively affecting β-cell differentiation or functional status. Finally, we show that the proproliferative mammalian target of rapamycin pathway is activated after Yap expression, providing at least one explanation for the observed increases in β-cell proliferation. Together, these results provide a foundation for manipulating Yap activity as a novel approach to expand functional islet mass for diabetes regenerative therapy.

AB - Loss of pancreas β-cell function is the precipitating factor in all forms of diabetes. Cell replacement therapies, such as islet transplantation, remain the best hope for a cure; however, widespread implementation of this method is hampered by availability of donor tissue. Thus, strategies that expand functional β-cell mass are crucial for widespread usage in diabetes cell replacement therapy. Here, we investigate the regulation of the Hippo-target protein, Yesassociated protein (Yap), during development of the endocrine pancreas and its function after reactivation in human cadaveric islets. Our results demonstrate that Yap expression is extinguished at the mRNA level after neurogenin-3-dependent specification of the pancreas endocrine lineage, correlating with proliferation decreases in these cells. Interestingly, when a constitutively active form of Yap was expressed in human cadaver islets robust increases in proliferation were noted within insulin-producing β-cells. Importantly, proliferation in these cells occurs without negatively affecting β-cell differentiation or functional status. Finally, we show that the proproliferative mammalian target of rapamycin pathway is activated after Yap expression, providing at least one explanation for the observed increases in β-cell proliferation. Together, these results provide a foundation for manipulating Yap activity as a novel approach to expand functional islet mass for diabetes regenerative therapy.

UR - http://www.scopus.com/inward/record.url?scp=84946096055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946096055&partnerID=8YFLogxK

U2 - 10.1210/me.2014-1375

DO - 10.1210/me.2014-1375

M3 - Article

VL - 29

SP - 1594

EP - 1607

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 11

ER -